Cargando…

Statin utilisation in a real‐world setting: a retrospective analysis in relation to arterial and cardiovascular autonomic function

Randomized trials suggest that statin treatment may lower blood pressure and influence cardiovascular autonomic function (CVAF), but the impact of duration of usage, discontinuation, and adherence to this therapy is unknown. We examined these issues with regard to blood pressure (BP)‐related variabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sluyter, John D., Hughes, Alun D., Lowe, Andrew, Camargo, Carlos A., Scragg, Robert K. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226288/
https://www.ncbi.nlm.nih.gov/pubmed/28097009
http://dx.doi.org/10.1002/prp2.276
Descripción
Sumario:Randomized trials suggest that statin treatment may lower blood pressure and influence cardiovascular autonomic function (CVAF), but the impact of duration of usage, discontinuation, and adherence to this therapy is unknown. We examined these issues with regard to blood pressure (BP)‐related variables in a large, population‐based study. Participants were 4942 adults (58% male; aged 50–84 years): 2179 on statin treatment and 2763 untreated. Days of utilization, adherence (proportion of days covered ≥0.8), and discontinuation (non‐use for ≥30 days immediately prior to BP measurement) of three statins (atorvastatin, pravastatin, and simvastatin) over a period of up to 2 years was monitored retrospectively from electronic databases. Systolic BP (SBP), diastolic BP (DBP), augmentation index, excess pressure, reservoir pressure, and CVAF (pulse rate and BP variability) parameters were calculated from aortic pressure waveforms derived from suprasystolic brachial measurement. Days of statin treatment had inverse relationships with pulse rate variability parameters in cardiac arrhythmic participants (20–25% lower than in statin non‐users) and with most arterial function parameters in everyone. For example, compared to untreated participants, those treated for ≥659 days had 3.0 mmHg lower aortic SBP (P < 0.01). Discontinuation was associated with higher brachial DBP and aortic DBP (for both, β = 2.0 mmHg, P = 0.008). Compared to non‐adherent statin users, adherent users had lower levels of brachial SBP, brachial DBP, aortic DBP, aortic SBP, and peak reservoir pressure (β = −1.4 to −2.6 mmHg). In conclusion, in a real‐world setting, statin‐therapy duration, non‐discontinuation and adherence associate inversely with BP variables and, in cardiac arrhythmias, CVAF parameters.